Trueline Therapeutics Inc.

MCL1 Inhibitor


MCL1 is a member of the Bcl-2 family which acts as a “brake” on the apoptosis pathway which normally clears unwanted cells. In many human cancers, the Mcl-1 gene is amplified, shifting the balance between pro- and anti-apoptotic signals and promoting cancer cell survival and tumor formation.

Pressing the 'Red Button' to kill cancer

Cancer cells ensure their uncontrolled growth by heavily leaning on anti-apoptotic proteins like MCL1. Targeting MCL1 rapidly pushes cancer cells down the irreversible path to death.

Hello world

TTX-810 - MCL1 inhibitor

Tailored to biology

MCL1 is a key component in cancer cell survival and the one of the main cause for resistance to current standard of care. Targeting MCL1 rapidly induces to apoptotic pathway and irreversible path to cancer cell death. Targeting MCL1 has been accepted as attractive treatment option for cancer patients, yet first generation inhibitors failed due to on target cardiotoxicity. TruelineTx scientists led 10+ years of research to identify TTX-810, the next generation MCL1 inhibitor which leverages anti-tumor activity while avoiding on-target toxicities. TTX-810 selectively inhibits MCL1 function and induces rapid and specific killing of cancer cells in preclinical models when administered as a single agent or in combination with other targeted therapies. Now, it’s full steam ahead to bring this powerful therapeutic agent to patients.

For partnerships, investment opportunities, or to learn more about our work, contact us.